Jentashapir Journal of Health Research

Published by: Kowsar

Determination of Sex Hormones, Glucose Tolerance Test and Insulin Concentrations in Prediction of Clomiphene Citrate Efficacy in Polycystic Ovary Syndrome

Farideh Moramezi 1 , * , Najmieh Sadati 1 and Zohre Aboutalebi 1
Authors Information
1 Fertility, Infertility and Perinatology Research Center, Imam Khomeini Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jentashapir Journal of Health Research: June 01, 2015, 6 (3); e27174
  • Published Online: June 27, 2015
  • Article Type: Research Article
  • Received: April 12, 2014
  • Accepted: January 24, 2015
  • DOI: 10.5812/jjhr.27174

To Cite: Moramezi F, Sadati N, Aboutalebi Z. Determination of Sex Hormones, Glucose Tolerance Test and Insulin Concentrations in Prediction of Clomiphene Citrate Efficacy in Polycystic Ovary Syndrome, Jentashapir J Health Res. 2015 ; 6(3):e27174. doi: 10.5812/jjhr.27174.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992; 57(3): 505-13[PubMed]
  • 2. Kidson W. Polycystic ovary syndrome: a new direction in treatment. Med J Aust. 1998; 169(10): 537-40[PubMed]
  • 3. Lobo RA. A disorder without identity: "HCA," "PCO," "PCOD," "PCOS," "SLS". what are we to call it?! Fertil Steril. 1995; 63(6): 1158-60[PubMed]
  • 4. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited. Fertil Steril. 1984; 42(3): 331-44[PubMed]
  • 5. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997; 3(4): 359-65[PubMed]
  • 6. Maxson WS, Pittaway DE, Herbert CM, Garner CH, Wentz AC. Antiestrogenic effect of clomiphene citrate: correlation with serum estradiol concentrations. Fertil Steril. 1984; 42(3): 356-9[PubMed]
  • 7. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 1993; 59(2): 323-31[PubMed]
  • 8. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig. 2003; 10(2): 99-104[PubMed]
  • 9. Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf). 1990; 33(2): 271-8[PubMed]
  • 10. Kato J, Kobayashi T, Villec CA. Effect of clomiphene on the uptake of estradiol by the anterior hypothalamus and hypophysis. Endocrinology. 1968; 82(5): 1049-52[DOI][PubMed]
  • 11. Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril. 1977; 28(7): 707-17[PubMed]
  • 12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774-800[DOI][PubMed]
  • 13. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001; 75(1): 53-8[PubMed]
  • 14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11): 4237-45[DOI][PubMed]
  • 15. Dunaif A. Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome. Fertil Steril. 2003; 80(2): 262-3[PubMed]
  • 16. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009; (4)[DOI][PubMed]
  • 17. Moolenaar LM, Nahuis MJ, Hompes PG, van der Veen F, Mol BW. Cost-effectiveness of treatment strategies in women with PCOS who do not conceive after six cycles of clomiphene citrate. Reprod Biomed Online. 2014; 28(5): 606-13[DOI][PubMed]
  • 18. Yazici G, Savas A, Tasdelen B, Dilek S. Role of luteal phase support on gonadotropin ovulation induction cycles in patients with polycystic ovary syndrome. J Reprod Med. 2014; 59(1-2): 25-30[PubMed]
  • 19. Kelekci S, Eris S, Demirel E. Ultra-short term clomiphene citrate in high responder women with polycystic ovary syndrome: a case series. Eur J Obstet Gynecol Reprod Biol. 2014; 175: 191-3[DOI][PubMed]
  • 20. Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, et al. Population study of causes, treatment, and outcome of infertility. Bmj. 1985; 291(6510): 1693-7[DOI]
  • 21. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003; 18(9): 1928-32[PubMed]
  • 22. Amooee S, Parsanezhad ME, Ravanbod Shirazi M, Alborzi S, Samsami A. Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial. Iran J Reprod Med. 2013; 11(8): 611-8[PubMed]
  • 23. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod. 2008; 23(10): 2352-8[DOI][PubMed]
  • 24. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006; 91(2): 492-7[DOI][PubMed]
  • 25. Helmrath MA, Brandt ML, Inge TH. Adolescent obesity and bariatric surgery. Surg Clin North Am. 2006; 86(2): 441-54[DOI][PubMed]
  • 26. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004; 59(5): 368-78[PubMed]
  • 27. Jungheim ES, Lanzendorf SE, Odem RR, Moley KH, Chang AS, Ratts VS. Morbid obesity is associated with lower clinical pregnancy rates after in vitro fertilization in women with polycystic ovary syndrome. Fertil Steril. 2009; 92(1): 256-61[DOI][PubMed]
  • 28. Biro FM, Emans SJ. Whither PCOS? The challenges of establishing hyperandrogenism in adolescent girls. J Adolesc Health. 2008; 43(2): 103-5[DOI][PubMed]
  • 29. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87(3): 1017-23[DOI][PubMed]
  • 30. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004; 59(2): 141-54[DOI][PubMed]
  • 31. Banaszewska B, Spaczynski RZ, Pelesz M, Pawelczyk L. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst. 2003; 48: 131-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments